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Placental dysfunction is implicated in many major complications of pregnancy associated with adverse
maternal and infant outcome, such as preeclampsia, fetal growth restriction and stillbirth. Yet, despite
years of intensive research, screening for these complications is still largely based upon clinical grounds
rather than ultrasonic and/or biochemical assessment of placental function. One of the few widely
employed methods for assessment of risk, low ﬁrst trimester levels of PAPP-A (Pregnancy Associated
Plasma Protein A), was identiﬁed through secondary analysis of data collected to identify new methods
of screening for Down's syndrome rather than as a purposeful search for screening tests for abnormal
placentation. Development of improved methods for population screening requires better mechanistic
understanding of the pathways leading to placentally-related complications of human pregnancy. This is
in addition to a need for identiﬁcation of biomarkers which reﬂect the underlying pathology, while
predicting associated disease with high sensitivity and speciﬁcity. In this paper, we outline some of the
challenges and opportunities in this area. Furthermore, we illustrate how some of these can be addressed
in research studies using the example of the Pregnancy Outcome Prediction (POP) study, a prospective
cohort study conducted in Cambridge, UK.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
1.1. Clinical context
Pregnancies complicated by preeclampsia (PE) and fetal growth
restriction (FGR) are associated with an increased risk of maternal
and perinatal morbidity, as well as mortality [1,2]. FGR is estimated
to be the underlying cause in 30e50% cases of stillbirths [3].
Moreover, FGR and PE are deﬁned as placentally-related compli-
cations in a large proportion of cases, as they are often character-
ized by defective placental development (e.g. inadequate re-
modelling of maternal spiral arteries and altered uteroplacental
blood perfusion) [4]. Therefore placental dysfunction is one of thend Gynaecology, University of
B2 0SW, UK.
equally to this work.
r Ltd. This is an open access article
et al., The pregnancy outcome
ental phenotype and adverunderlying factors which contribute to PE and FGR, and conse-
quently stillbirth. This offers a great opportunity to identify women
at risk using biomarkers reﬂecting defective placentation.
Currently, antenatal care of ﬁrst pregnancies in UK involves 10
routine midwife visits (Fig. 1A). Such high intensity reﬂects a poor
discrimination of risk: most severe adverse outcomes in ﬁrst
pregnancies occur to women who are deemed to be “low risk” at
booking. Moreover, the primary screening method for women is for
the midwife to measure symphyseal-fundal height with a tape
measure, check blood pressure and test urine for proteinuria. The
only widely used biomarker for placentally-related complications
(low ﬁrst trimester PAPP-A, see below) was the result of secondary
analysis of Down's syndrome screening studies. An alternative to
the current approach is personalised antenatal care, where the
pattern and frequency of visits is proportionate to the given
woman's risk of key complications, as estimated by the patient's
clinical records, medical imaging and/or biomarkers. This could
avoid unnecessary intervention in healthy women and facilitate theunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
prediction (POP) study: Investigating the relationship between serial
se pregnancy outcomes, Placenta (2016), http://dx.doi.org/10.1016/
F. Gaccioli et al. / Placenta xxx (2016) 1e92targeting of resources in a more cost-effective and clinically effec-
tivemanner for high risk women.We are attempting to address this
goal by conducting a prospective cohort study of unselected
nulliparous women, focusing on serial ultrasonography measure-
ments and collection of biological samples. In this article we outline
rationale and conduct of the study, while addressing some generalFig. 1. A) Standard antenatal care for nulliparous women in the UK, including 10 routine mid
POP study.
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Fetal growth is evaluated using ultrasonographic fetal biometry
and calculation of estimated fetal weight (EFW). Placental functionwife visits and additional visits for women delivering after 40wkGA. B) Flow chart of the
prediction (POP) study: Investigating the relationship between serial
se pregnancy outcomes, Placenta (2016), http://dx.doi.org/10.1016/
Table 1
Numbers and rates of adverse outcomes of women participating in the POP study.
Outcome N ¼ 4212
GDM 192 (4.6)
Missing 6 (0.1)
Pre-eclampsia/hypertension
De novo PE, not severe 53 (1.3)
De novo PE, severe 93 (2.2)
Superimposed PE, not severe 85 (2.0)
Superimposed PE, severe 42 (1.0)
GH, not severe 62 (1.5)
GH, severe 23 (0.6)
Essential HT 99 (2.4)
Missing 5 (0.1)
sPTD 113 (2.7)
Missing 41 (1.0)
Induction of labour 1355 (32)
Mode of delivery
Spontaneous vaginal 2051 (49)
Assisted vaginal 992 (24)
Intrapartum caesarean section 726 (17)
Pre-labour caesarean section 424 (10)
Missing 19 (0.5)
Outcome of birth
Livebirth 4161 (99)
Miscarriage (pre-viable <24wks) 13 (0.3)
Termination of pregnancy <24wks 17 (0.4)
Termination of pregnancy 24wks 1 (0.0)
Stillbirth 11 (0.3)
Neonatal death 6 (0.1)
Missing 3 (0.1)
Any neonatal morbidity 292 (6.9)
Metabolic acidosis 45 (1.1)
5-min Apgar <7 42 (1.0)
Neonatal unit admission 240 (5.7)
Severe adverse perinatal outcome 39 (0.9)
Abbreviations: GDM ¼ gestational diabetes mellitus, PE ¼ preeclampsia, GH ¼
gestational hypertension, essential HT ¼ essential hypertension, sPTD ¼ sponta-
neous preterm delivery (23-36 completed weeks, <23 weeks included in the
missing category). Data were obtained from examination of the clinical case records
and by linkage to the hospital’s electronic databases and are expressed as n (%). Any
neonatal morbidity was deﬁned as one or more of the following: delivery with
metabolic acidosis (cord blood pH <7.1 and base deﬁcit >10mmol/L), a 5-minute
Apgar score <7, or admission to neonatal unit at term (within 48 hours from
birth for at least 48 hours). Severe adverse perinatal outcome was deﬁned as one or
more of the following: stillbirth (not due to congenital anomaly), neonatal death at
term (not due to congenital anomaly), hypoxic ischaemic encephalopathy at term,
use of inotropes at term, mechanical ventilation at term, severe metabolic acidosis
at term (deﬁned as pH <7.0 and base deﬁcit >12 mmol/L). For characteristics that
have no “missing” category, data were 100% complete.
F. Gaccioli et al. / Placenta xxx (2016) 1e9 3is assessed using Doppler ﬂow velocimetry of the maternal uterine
and fetal umbilical arteries. Flow resistance of the uterine artery
decreases during the ﬁrst half of pregnancy due to invasion of the
maternal vessels by the trophoblast cells. Persistence of high
resistance patterns of ﬂow in both the uterine and umbilical artery
in mid-gestation and in the third trimester of pregnancy has been
associated with altered placental function and structure as well as
increased risk of obstetric complications [5e8]. Currently, these
methods are applied selectively to women with pre-existing risk
factors or acquired complications of pregnancy. However, the
sensitivity of selective use of ultrasonography for detecting small
babies is poor, in the region of 20e25% [9,10]. The obvious alter-
native, universal ultrasonography, is not recommended: systematic
reviews have failed to show an improvement in clinical outcome
with universal ultrasonography in late pregnancy [11]. However,
the apparent absence of beneﬁt may be due methodological
weaknesses [12], such as study heterogeneity, failure to design an
effective interventional strategy after the identiﬁcation of the
screen-positive cases, and lack of statistical power [13]. Although
there is no currently strong case for population-based screening
using universal ultrasound, this has been identiﬁed as a high pri-
ority for further research [14].
Currently in the UK, clinical guidelines recommend increased
surveillance of women having low ﬁrst trimester levels of the
placentally-derived protein PAPP-A [15,16]. However, this associa-
tion was found following secondary analyses of Down's syndrome
screening studies, which demonstrated that low maternal levels of
PAPP-A in the ﬁrst trimester were associated with PE, FGR and
stillbirth risk [17,18]. More recently other biochemical biomarkers
related to angiogenesis (i.e., Placental Growth Factor (PlGF), soluble
fms-like tyrosine kinase 1 (sFlt-1), soluble Endoglin (sEng)) have
been proposed as potential screening tests for PE and FGR [19e22].
Although potentially promising, their clinical usefulness has been
shown to be modest in several studies [19,23,24]. Their diagnostic
effectiveness as a screening test remains to be properly assessed in
low risk populations, close to term (when an effective intervention
is available, i.e. delivery of the baby), in association with different
phenotypes of the disease (especially in pregnancies with small
babies), and in combination with other biomarkers.
2. Designing a study for identiﬁcation of novel screening
appraoches
2.1. Overview, aims and design of POP study
The Pregnancy Outcome Prediction (POP) study is a prospective
cohort study of nulliparous women attending the Rosie Hospital
(Cambridge, UK) for their dating ultrasound scan [25]. The study
included 4512 women with a viable singleton pregnancy; study
participants provided written informed consent and were recruited
between January 2008 and July 2012 (Fig. 1B) [10]. The rationale
behind recruiting only nulliparous women is that they have a
higher absolute risk of developing pregnancy complications
compared to multiparous women [26,27]. Furthermore, they lack
previous pregnancy outcome information which is an important
risk indicator for subsequent pregnancies [28,29].
The POP study aimed both at evaluating performance of known
biomarkers and serial ultrasonography in assessing maternal and
fetal well-being, as well as identifying novel biomarkers. The study
is sufﬁciently large to be powered for relatively uncommon adverse
pregnancy outcomes (Table 1) [25]. Women attended four study
visits scheduled every 8 weeks, starting with the ﬁrst trimester.
Participants had blood taken during the dating/recruitment visit (at
approximately 12 weeks gestation (wkGA)), as well as at three
subsequent visits (at ~20wkGA, ~28wkGA and ~36wkGA). On eachPlease cite this article in press as: F. Gaccioli, et al., The pregnancy outcome
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to assess fetal biometry, amniotic ﬂuid index, uterine and umbilical
uterine artery Doppler ﬂow velocimetry and placental maturity.
Serial measurements and sampling offer the chance to monitor the
parameters of interest throughout gestation, and changes across
pregnancy have been suggested to have more predictive power
than single snapshots in time [30,31]. The ﬁnal evaluation at
36wkGA was intended as a means to screen for risk of complica-
tions at term, when effective intervention to prevent placentally-
related complications of pregnancy is available (i.e., early de-
livery). The timing of this visit was informed by previous analyses
demonstrating that tests of placental dysfunction (i.e., biochemical
and ultrasonic screening) have a better predictive value when
performed close to disease onset [32]. Patients and clinicians were
blinded to these ultrasonography results, unless major congenital
abnormalities, placenta praevia, severe oligohydramnios or breech
presentation (36wkGA only) were detected. At the 20wkGA visit, a
questionnaire was completed to retrieve the patient's demographic
data andmedical history. During the same visit a DNA sample of the
partner and measurements of the partner's height/weight were
collected. After delivery, biopsies of the placenta, placentalprediction (POP) study: Investigating the relationship between serial
se pregnancy outcomes, Placenta (2016), http://dx.doi.org/10.1016/
F. Gaccioli et al. / Placenta xxx (2016) 1e94membranes, umbilical cord, and cord blood were collected (see
below).
A further point of note is that the population in the POP study is
low risk and homogeneous, from a demographic and socio-
economic perspective (Table 2). The low risk nature of the cohort
is an important study strength from the perspective of both eval-
uating screening tests and identifying novel mechanisms/bio-
markers of placental dysfunction. It is well-recognized that studies
can overestimate the positive predictive value of a screening test byTable 2
Characteristics of the POP study cohort. Hospital record data comparing women
recruited to the POP study (Cambridge, UK) with eligible women who were not
recruited.
Characteristic Recruited
N ¼ 4265
Not recruited
N ¼ 2909
P Value
Age, years
<20 115 (2.7) 166 (5.7) <0.0001a
20e24.9 527 (12) 550 (19)
25e29.9 1210 (28) 876 (30)
30e34.9 1637 (38) 901 (31)
35e39.9 668 (16) 353 (12)
40 108 (2.5) 63 (2.2)
BMI, kg/m2
<25 2339 (55) 1634 (56) 0.10
25e29.9 1009 (24) 629 (22)
30e34.9 330 (7.7) 198 (6.8)
35e39.9 106 (2.5) 86 (3.0)
40 60 (1.4) 33 (1.1)
Missing 421 (9.9) 329 (11)
White ethnicity 3914 (92) 2490 (86) <0.0001
Missing 62 (1.5) 46 (1.6)
Smoker at booking 347 (8.1) 350 (12) <0.0001
Missing 188 (4.4) 141 (4.9)
1 previous miscarriage
(1st trimester)
540 (13) 297 (10) 0.003
1 previous miscarriage
(2nd trimester)
108 (2.5) 57 (2.0) 0.15
Mode of delivery
Vaginal 2094 (49) 1537 (53) 0.0002
Assisted vaginal 1006 (24) 702 (24)
Caesarean section 1165 (27) 670 (23)
Gestational age, weeks
Preterm: <24 22 (0.5) 18 (0.6) 0.29a
Preterm: 24-<33 43 (1.0) 32 (1.1)
Preterm: 33-<37 156 (3.7) 119 (4.1)
Term: 37 4012 (94) 2727 (94)
Missing 32 (0.8) 13 (0.4)
Birth weight centile
SGA (<10th) 390 (9.1) 298 (10) 0.13
Severe SGA (<3rd) 102 (2.4) 94 (3.2) 0.03
Missing 55 (1.3) 33 (1.1)
Transfer to neonatal unit 216 (5.1) 176 (6.1) 0.07
Missing 34 (0.8) 18 (0.6)
Outcome of birth
Livebirth 4231 (99) 2889 (99) 0.75
Miscarriage 5 (0.1) 3 (0.1)
Termination of pregnancy 18 (0.4) 12 (0.4)
Stillbirth 11 (0.3) 4 (0.1)
Missing 0 (0) 1 (0.03)
Abbreviations: BMI ¼ body mass index, SGA ¼ small for gestational age. Data are
expressed as median (inter-quartile range) or n (%) as appropriate. P-values are for
difference between groups calculated using the two-sample Wilcoxon rank-sum
(Mann-Whitney) test for continuous variables and the Pearson Chi-square test for
binary and categorical variables.
a Score test for trend of odds is reported for categorical ordered variables if the
trend is approximately linear. For ﬁelds where there is no category labelled
“missing”, data were 100% complete. Maternal age is deﬁned as age at delivery.
Missing category is not included in statistical tests. The hospital's delivery database
(PROTOS) was used to compare basic characteristics of women recruited to the
study and eligible women who were not recruited. Recruited N ¼ 4512 minus 247
who delivered elsewhere and had no PROTOS record ¼ 4265. Not recruited
N ¼ 3516 eligible minus 607 without PROTOS record ¼ 2909. Modiﬁed from Sovio
et al. (2015) [10].
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eral population (called the “spectrum effect”) [33]. Moreover, when
studying mechanisms it would clearly be problematic if cases were
largely derived from a population of different ethnicity and socio-
economic status than controls. This is a potential hazard as many
placentally-related complications of pregnancy are more common
in minority and socio-economically deprived communities.
2.2. Other prospective cohort studies: NuMoMs2b and SCOPE
Other prospective cohort studies recruiting nulliparous women
with singleton pregnancies have been conducted, such as the
Nulliparous Pregnancy Outcome study: Monitoring Mother-to-be
(NuMoMs2b) and the Screening for Pregnancy Endpoints (SCOPE)
[34,35]. Approximately 10,000 women were recruited in the
NuMoMs2b study in multiple centres across the United States. The
SCOPE study was a multicentre cohort study including about 5500
women in Australia, Ireland, New Zealand, and the United
Kingdom. As in the POP study, women enrolled in the SCOPE and
NuMoMs2b studies were recruited in early pregnancy, at ~12-
16wkGA. Although the cohort populations are similar in the three
studies, there are some important differences. For instance, in the
SCOPE and NuMoMs2b studies the last study visits were conducted
at ~24wkGA and ~28wkGA, respectively, therefore excluding a
collection point close to term which may be important for pre-
dicting adverse pregnancy outcome [32]. Additionally, placental
samples were collected from a small percentage of the participants
in the NuMoMs2b study and the SCOPE study did not include
routine placenta collection. Finally, all three studies performed
research ultrasound examinations. However, the results of these
scans were reported in both SCOPE and NuMoMs2b, whereas in
POPs the results were blinded in >94% of cases. One of the criteria
for a Level 1 study of diagnostic effectiveness is blinding results
from the screening test being evaluated, in this case serial universal
ultrasonography [10].
2.3. Multiple methodological approaches around a single study
Since the POP study is a large prospective study, it offers the
possibility of analysing parameters and values measured at a spe-
ciﬁc gestational, but also changes over time. This has been sug-
gested to be useful in the search of biomarkers for pregnancy
complications [30,31]. Moreover, multiple approaches are available
for sample and data analysis, which can be carried out on thewhole
study cohort or subsets of participants. Alternative methodological
approaches can be used, such as case-cohort study and nested,
matched case-control study.
2.3.1. Prospective cohort study
When using this type of analysis, data available from all the
study participants (such as ultrasound scan results and maternal
demographic information) are employed to calculate incidence
rates, relative risks, and conﬁdence intervals [36]. This approach
has been used to compare the detection rates of small for gesta-
tional age (SGA) infants using selective and universal ultrasound
[10]. Here, blinding of the research ultrasonographywas crucial and
this is, to our knowledge, the only large scale Level 1 study of the
diagnostic effectiveness of universal ultrasound as a screening test
for SGA. Several other papers on results from the POP study have
been published using this methodology (details below).
2.3.2. Case-cohort study
A case-cohort methodological approach utilises all cases (of
differing types; i.e., PE, gestational diabetes, FGR) within the cohort
and a randomly selected sub-cohort as control group [37]. Thus forprediction (POP) study: Investigating the relationship between serial
se pregnancy outcomes, Placenta (2016), http://dx.doi.org/10.1016/
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controls. Such an approach may be advantageous if expensive or
labour intensive assays are being performed, since it reduces the
number of samples processed while still achieving a similar pre-
cision compared to using measurements from the whole cohort.
Similar to whole cohort analysis, calculation of relative risks is
possible using a case-cohort methodological approach. This design
is currently being used in the POP study to investigate metabolomic
markers of a range of pregnancy outcomes.
2.3.3. Nested matched case-control study
With a nested case-control methodological approach, identiﬁed
cases within a larger cohort are selected and matched one-to-one
with healthy controls [36]. Cases are paired with controls based
upon key characteristics (e.g., maternal body mass index (BMI),
gestational age (GA), and fetal sex) and statistical comparisons are
based on paired methods (e.g., paired t-test for continuous vari-
ables and the McNemar test for dichotomous variables). Therefore,
potential confounders are adjusted through matching. The nested
case-control approach is particularly useful for molecular studies
where methodologies are very expensive and/or labour intensive,
as well as when adjustments using multivariate statistical models
are not applicable. In the POP study there are currently several
projects with this design, based on Next Generation Sequencing
(NGS) and histological examinations of placental specimens (dis-
cussed below).
2.3.4. Synergies between study designs
A key element of the POP study is that data used for one element
of the analysis can strengthen other aspects of the analysis. For
example, the results of uterine and umbilical Doppler ﬂow veloc-
imetry were employed in the analysis of universal ultrasound as a
screening test for SGA and FGR. The same data then allows SGA
infants to be phenotyped in greater detail. We can show that better
phenotyping of SGA cases results in a much larger number of
positive results in RNA-Seq analysis (see below). We thereby
conclude that heterogeneity within groups with apparently similar
outcomes can mask differences between cases and controls.
3. Current ﬁndings
Several projects planned with samples from the POP study are
currently ongoing: the analysis of clinical records and outcome data
parallels and complements the wet lab work.
3.1. Ultrasonographic fetal biometry
Historically, fetal biometry measurements had a particular focus
upon the identiﬁcation of SGA babies [38]. As described above,
clinically indicated ultrasonography in the third trimester has a low
sensitivity (20e25%) for detecting SGA babies [9,10]. We demon-
strated that screening of nulliparous, low risk women with uni-
versal third trimester fetal biometry triples the detection of SGA
infants [10]. Moreover, analysis of the abdominal circumference
(AC) growth velocity was the most effective method for discrimi-
nating between healthy SGA infants and those with FGR.
Other recent analyses of the POP study cohort have yielded in-
sights from serial assessment of fetal biometry. We have reported
that reduced fetal growth velocity of the femur between 20 and
28wkGA was associated with a ~2.5 fold increased risk of sponta-
neous preterm birth [39]. We have also reported associations with
excessive growth. We found that maternal diagnosis of gestational
diabetes mellitus (GDM) at or after 28wkGA was preceded by
excessive AC growth between 20 and 28wkGA; GDM effects on fetal
growth were additive with the effects of maternal obesity [40].Please cite this article in press as: F. Gaccioli, et al., The pregnancy outcome
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around 28wkGA, data indicate that earlier screening and inter-
vention may result in better control of excessive fetal growth.
3.2. Automated immunoassay analysis of maternal serum samples
Although maternal blood is an easily accessible and attractive
resource of potential biomarkers for pregnancy complications, the
factors studied so far revealed low predictive power for PE and FGR.
The maternal serum samples collected in the POP study at
~12wkGA, ~20wkGA, ~28wkGA and ~36wkGA have been analysed
to determine whether combination of universal ultrasound and
previously described placental biomarkers may improve identiﬁ-
cation of pregnancies at increased risk of adverse outcome. A total
of 15,874 serum samples from the 4212 womenwho completed the
study have been analysed using clinical grade Roche Elecsys im-
munoassays on an electro-chemiluminescence platform (cobas
e411 analyzer, Roche Diagnostics, Mannheim, Germany). We ana-
lysed levels of proteins where there is a clinical grade assay avail-
able and where previous studies have shown associations with
placental function: alpha fetoprotein (AFP), chorionic gonadotropin
(hCG), PAPP-A, PlGF, and sFlt-1. All the samples have been pro-
cessed and the analysis in relation to the pregnancy outcomes is
currently ongoing. Interestingly, a plot of the raw data demon-
strates that the 5 proteins show different patterns of change in
relation to gestational age, suggesting that each reports different
aspects of placental function (Fig. 2).
3.3. Placental morphometry and histology
A series of photographs were taken ofmaternal and fetal sides of
the whole placenta, as well as 1 cm thick strips (Fig. 3) [https://
www.obgyn.cam.ac.uk/research/pops-2/]. Using these images, the
relation between prenatal ultrasonic measurements and postnatal
placental morphometry has been investigated [6]. We demon-
strated that reduced placental surface area is associated with high
resistance uterine artery Doppler at 20wkGA, while lower placental
weight is associated with high resistance umbilical Doppler at
36wkGA. Furthermore, reduced placental surface area and
placental weight are associated with reduced fetal growth velocity.
Several ongoing projects are based upon histopathological
analysis of placental biopsies. For example, we are currently
studying matched case-control pairs, focusing on both PE and FGR.
3420 biopsies from 855 placentas have been ﬁxed and cut for mi-
croscopy (Fig. 3). Each biopsy is analysed using nine stains (he-
matoxylin and eosin (H&E), 5-hydroxymethylcytosine, CD14, CD3,
CD31, CD4, CD79a, CD8, and neutrophil elastase), for a total of
30,780 biopsies stained using the fully automated platform BOND-
III (Leica Biosystems). High-resolution images are generated by an
Aperio AT2 scanner (Leica Biosystems). These are analysed quan-
titatively and blind to clinical outcome using a Visiopharm com-
puter assisted stereology toolbox and image analysis. H&E sections
are also being reported by two perinatal pathologists who are blind
to outcome.
3.4. Next Generation Sequencing (NGS)
NGS is one of the major methods of analysis employed in
studying placental biopsies, with a focus both on the transcriptome
and the epigenome (small RNAs, DNA methylation and histone
modiﬁcations). These analyses have the following aims: (i) under-
standing the mechanisms leading to placentally-related complica-
tions, (ii) studying the association between pregnancy
complications and the presence of infectious agents in the placenta,
and (iii) identifying of novel biomarkers that can be evaluated inprediction (POP) study: Investigating the relationship between serial
se pregnancy outcomes, Placenta (2016), http://dx.doi.org/10.1016/
Fig. 2. Biomarkers measured in maternal serum samples from women completing the study (n ¼ 4212). A) AFP, B) hCG, C) PAPP-A, D) PlGF, E) sFlt-1, and F) the ratio of sFlt-1/PlGF
were measured in serum samples collected at ~12wkGA (n ¼ 4078), ~20wkGA (n ¼ 4021), ~28wkGA (n ¼ 3994), and ~36wkGA (n ¼ 3780). Samples were analysed using clinical
grade Roche Elecsys immunoassays on an e411 platform (Roche). The red lines indicate the 50th percentile values and the black lines represent the 5th and 95th percentile values at
12, 20, 28 and 36 completed weeks of GA ± 2 weeks difference.
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Fig. 3. Overview of placental sampling. A) Tissue biopsies were collected from umbilical cord, fetal membranes, and villous tissue. For the villous tissue, four collection points were
selected and the samples from each collection point stored separately. Samples for DNA or Protein were snap frozen in liquid nitrogen and then stored at 80 C. Biopsies for RNA
extraction were soaked in RNAlater overnight (4 C) and then frozen in liquid nitrogen and stored at 80 C. All samples for histology were ﬁxed in formalin for 24 h (4 C) before
being embedded in parafﬁn wax. A full thickness wedge biopsy was collected from the edge of the placenta. If the placenta was processed more than 30 min after delivery, RNA and
cord blood samples were not collected. B) After processing the tissue biopsies, the fetal membranes and the umbilical cord were trimmed off and photographs of the placenta were
taken, both of the maternal side (basal plate) and fetal side (chorionic plate). C) Lastly, each placenta was cut along its longest diameter into 1 cm thick sections with the fetal side
facing upward. The sections were tipped, exposing the cut surface (fetal side to the right and maternal side to the left) and a photograph was taken. In each photograph a ruler and a
label with a unique sample ID number were included.
F. Gaccioli et al. / Placenta xxx (2016) 1e9 7the matched blood samples. This broad approach has previously
yielded novel markers. Using older expression array-based tech-
nology, it was discovered that excess placental production of sFlt1
contributes to increased maternal circulating sFlt-1 in pregnancies
complicated by PE [41]. Circulating sFlt-1 measurements, combined
with PlGF levels, have been shown to be useful in the assessment of
PE. High sFlt-1 concentrations and increased sFlt-1:PlGF ratio have
been measured in women who later developed PE ﬁve weeks
before the clinical onset of the disease [42,43]. The same authors
reported that an high sFlt-1:PlGF ratio is highly predictive of PE
when tested in combination with soluble endoglin levels. More-
over, sFlt-1:PlGF ratio has now been shown to be clinically useful in
ruling out preeclampsia within one week after the test when the
condition is suspected [44].
In the POP study, a total of 320 placental samples (from 55
matched severe SGA [<5th percentile]/appropriate for gestational
age (AGA) pairs, and 105 matched PE/control pairs) have been
studied using RNA-Seq analysis of both long RNAs (i.e., totRNA-seq
identifying mRNAs and lncRNAs) and small RNAs (i.e., smallRNA-
seq identifying miRNAs and piRNAs). This work has generated
large volumes of data. For example, in the projects based on
totRNA-Seq, we have an average of 102 million reads (125 base pair
long, single end) per sample, resulting in a total of ~33 billion reads.
The differentially expressed RNAs or the corresponding coded
proteins, in case of altered mRNAs, will be later studied in thePlease cite this article in press as: F. Gaccioli, et al., The pregnancy outcome
prenatal ultrasonography, biomarkers, placental phenotype and adver
j.placenta.2016.10.011maternal circulation. In these NGS-based projects, information
derived from the clinical records and outcome data collected in the
POP study were used not only to identify and characterise disease
subtypes, but also to carefully match cases and controls (e.g., ac-
cording to GA, maternal BMI and age, smoking, fetal sex, labour, and
mode of delivery). The nested case-control design has a higher
statistical power than unmatched designs and it accounts for
confounding through matching, as described above. Interestingly,
the initial analysis of the results from the SGA/AGA pairs revealed
that the accurate deﬁnition of clinical subgroups of SGA (i.e., small
healthy babies or small babies with poor AC growth velocity, SGA
pregnancies with high resistance umbilical Doppler, high resistance
uterine Doppler, low maternal PAPP-A, or maternal hypertension)
led to the identiﬁcation of a higher number of differentially
expressed RNAs compared to an analysis including all the SGA
samples. This ﬁnding illustrates the importance of deep pheno-
typing of cases when the outcome can be the end point of multiple
different pathological processes.
4. Conclusions
Careful design of a large prospective study involves accurate
collection and storage of clinical information, outcome data and
biological samples (Fig. 4). Clinical information helps deﬁning the
biological samples and, likewise, the results obtained from theprediction (POP) study: Investigating the relationship between serial
se pregnancy outcomes, Placenta (2016), http://dx.doi.org/10.1016/
Fig. 4. The POP study at a glance. Each coloured area includes clinical data/measurements or samples collected during the study and their corresponding results/projects. Patients'
clinical data are managed using electronic databases of ultrasonography (Astraia, München, Germany), neonatal intensive care (Badgernet, Clevermed Ltd, Edinburgh, UK),
biochemical tests (Meditech, Westwood MA, USA) and delivery (Protos, iSoft, Banbury, UK). Approximately 230,000 blood and tissue samples are stored in six 80 C freezers (with
empty backup freezer, backup power supply, telephone alert system and automatic triggering of liquid CO2 to maintain the temperature at 65 C in the event of failure). All
samples are labelled with identiﬁers and unique 2D barcodes and tracked using Pro-curo software (Pro-curo Software Ltd, Horsham, UK). N indicates the number of patients from
whom the samples/records were obtained; n indicates the number of samples analysed. Abbreviations: HLA ¼ human leukocyte antigen, KIR ¼ Killer-cell immunoglobulin-like
receptor.
F. Gaccioli et al. / Placenta xxx (2016) 1e98biological samples contribute to accurate phenotyping of the pa-
tient and the pregnancy. Moreover, such a design allows the
identiﬁcation of clinically useful biomarker candidates. These
considerations need to be taken into account when designing a
study ultimately aiming at improving management of patients and
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